|Bid||144.99 x 200|
|Ask||158.10 x 100|
|Day's Range||143.54 - 146.05|
|52 Week Range||137.17 - 192.15|
|PE Ratio (TTM)||27.40|
|Forward Dividend & Yield||0.92 (0.63%)|
|1y Target Est||N/A|
In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.
Shire (SHP.L) ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta. Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".
Rare disease drugmaker Shire cut its 2020 revenue forecast on Monday, and announced that it plans to split its ADHD drugs into a separate division, with a possible spinout in the future. Shire (SHPG), the state’s second largest biopharma employer, said that it is now projecting its total revenue to reach $17 billion to $18 billion by 2020. Shares of Shire were down more than 4 percent as of 11 a.m., shaving nearly $2 billion off its market capitalization, which was around $45 billion before the selloff.
London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group. Shire said that following a review it had decided its neuroscience business, which makes the attention deficit hyperactivity disorder (ADHD) blockbuster Vyvanse, warranted additional focus and investment. "Shire has undergone a significant transformation over the last five years creating two market-leading businesses with distinct profiles and future needs," chief executive Flemming Ornskov said.
In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.
Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday. "The question is will the FDA accept this or make them do another trial before approval?" Wedbush analyst Liana Moussatos told Reuters, dubbing Kala's first trial "the best results" for dry eye she'd seen in a late-stage study.
Categories: Yahoo FinanceGet free summary analysis Shire Plc reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 3,720.03 million, Net Earnings of USD 554.54 million. Gross margins widened from 38.31% to 58.52% compared to the same period last year, operating (EBITDA) margins now 42.01% from 12.23%. Change in operating cash ... Read more (Read more...)
Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.
Shares of Shire (SHPG) are lower on Wednesday, after the drug maker said it filed its first submission for its new plasma manufacturing facility in Georgia to the Food and Drug Administration. Cantor Fitzgerald's Louise Chen and her team write that the new facility will support Shire's immunology franchise, which has seen sales climb some 21% in 2017, easily above the 6% to 8% growth the company originally expected. SHPG guided to overall gross margins of 74.5%-76.5% in 2017 for the entire business, but did not break this out by business segments.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
The most recent earnings update Shire plc’s (LSE:SHP) released in September 2017 indicated that the business experienced a major headwind with earnings deteriorating by -54.88%. Below, I’ve presented key growthRead More...
Shire plc’s (NASDAQ:SHPG) most recent earnings announcement in September 2017 revealed that the business endured a immense headwind with earnings falling by -54.88%. Below, I’ve presented key growth figures onRead More...
Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial. The trial evaluated the efficacy of Shire's treatment, SHP609, based on changes in cognition between children treated with the drug and those on a placebo, the London-listed drugmaker said on Tuesday. Hunter syndrome is a rare, inherited metabolic disorder that mainly affects males.
The U.S.-listed shares of Shire PLC fell 1.2% in premarket trade Tuesday, after the Ireland-based drug maker said a phase 2/3 trial of its treatment for Hunter syndrome in pediatric patients failed to ...
Shire Plc's investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial. The clinical trial evaluating SHP609, ...
Roche's patent dispute with London-listed Shire over the Swiss drugmaker's new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine. Shire's motion for a preliminary injunction is part of an ongoing case in which it contends Roche infringed on a key patent to develop Hemlibra, approved in November by the U.S. Food and Drug Administration.
Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar receives approval from the European Commission.
Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.
Shire Plc said on Tuesday it had partnered with a California-based company to develop a new way to administer a drug to treat hemophilia A. The company, Rani Therapeutics, has developed a technology that will help oral delivery of peptides, proteins and therapeutic antibodies which to date could be delivered only through injections. Once delivered through Rani Pill - the oral delivery technology - the drug stays in the body until it enters the small intestine and transfers the medicine into the intestinal wall, the companies said.
With a market capitalization of £32.95B, Shire plc (LSE:SHP) falls in the category of stocks popularly identified as large-caps. These are established companies that attract investors due to diversified revenueRead More...
Today, Shire (SHPG) appointed a new chief financial officer. The shares are sliding lower today after its rival Roche (RHHBY) unveiled study results that showed its Hemlibra hemophilia drug trial reduced treated bleeds in hemophilia A patients without indicators. The news is an added blow for Shire.